HMO mixtures and bifidobacterium longum transition microorganisms

Intervention using a combination of Bifidobacterium longum transitional microorganisms and human milk oligosaccharides solved the problems of infant viral infection prevention and immune system regulation, achieving rapid disease regression and long-term immune benefits, and reducing the risk of respiratory viral infections and allergic diseases.

CN121909035APending Publication Date: 2026-04-21SOCIETE DES PRODUITS NESTLE SA
0 Cites 0 Cited by

Patent Information

Application Number
CN202480061970.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-09-27
Filing Date
2024-03-28
Publication Date
2026-04-21

AI Technical Summary

Technical Problem

There is a lack of effective strategies in the current technology to prevent and reduce the risk of viral infections in infants and young children, especially respiratory viral infections, and existing immune defense response dysregulation may lead to subsequent allergic or inflammatory diseases and chronic obstructive pulmonary disease.

Method used

A composition is provided comprising a mixture of Bifidobacterium longum transitional microorganism and specific human milk oligosaccharides, including 2'-fucosylated lactose, lactose-N-tetrasaccharide, etc., for use in early life for synbiotic intervention, regulating levels of protective cytokines and short-chain fatty acids, enhancing intestinal barrier function, and promoting appropriate immune system response.

Benefits of technology

Synbiotic intervention significantly reduces the risk of viral infection, promotes rapid disease resolution, reduces virus-induced lung inflammation, prevents allergen sensitization and respiratory symptoms, reduces asthma risk, and provides long-term immune benefits.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A mixture of HMO and a transition microorganism of Bifidobacterium longum. The present invention relates to a composition comprising a transition microorganism of Bifidobacterium longum and a mixture of human milk oligosaccharides (HMO) consisting of 2 '-fucosyllactose (2'-FL), difucosyllactose (DFL), lactose-N-tetraose (LNT), 6 '-sialyllactose (6SL) and 3'-sialyllactose (3SL) and optionally 3-fucosyllactose (3-FL) and / or lactose-N-neotetraose (LNnT). The invention also relates to the use of the composition for preventing, reducing the risk of, and / or treating an infection in an individual. The present invention also provides compositions for promoting long term immune benefit in an individual, preventing and / or reducing the risk of allergen sensitization, preventing and / or reducing the risk of developing a respiratory condition in an individual and / or preventing and / or reducing the risk of developing asthma in an individual.
Need to check novelty before this filing date? Find Prior Art